Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 6.15% is 120% above its 5-year average of -31.39%, near the high end of its 5-year range (-14856.41%–13.43%).
1266.30% above its 12-month average of 0.45%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 11.56%.
NET PROFIT MARGIN
6.15%
NET PROFIT MARGIN AVG TTM
0.45%
NET PROFIT MARGIN AVG 3Y
-45.65%
NET PROFIT MARGIN AVG 5Y
-31.39%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+1266.30%
CURRENT VS 3Y AVG
+113.47%
CURRENT VS 5Y AVG
+119.59%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+2465.38%
vs the sector median at left
Arcutis Biotherapeutics, Inc.
Market Cap
$2.99B
Net Profit Margin
6.15%
TTM Avg
0.45%
3Y Avg
-45.65%
5Y Avg
-31.39%
Market Cap
$3.03B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$3.06B
Net Profit Margin
-14191.20%
TTM Avg
0.00%
3Y Avg
-86.13%
5Y Avg
-153.41%
Market Cap
$2.88B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$3.12B
Net Profit Margin
0.00%
TTM Avg
-172.68%
3Y Avg
-306.20%
5Y Avg
-1288.24%
Market Cap
$3.19B
Net Profit Margin
-7.67%
TTM Avg
-38.94%
3Y Avg
-274.32%
5Y Avg
-186.92%
Market Cap
$2.77B
Net Profit Margin
22.69%
TTM Avg
19.73%
3Y Avg
-2.42%
5Y Avg
-44.65%
Market Cap
$2.73B
Net Profit Margin
1.85%
TTM Avg
-5.88%
3Y Avg
-8.36%
5Y Avg
-6.41%
Market Cap
$2.71B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | $2.99B | 6.15% | 0.45% | -45.65% | -31.39% |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.03B | 0.00% | 0.00% | 0.00% | 0.00% |
| Denali Therapeutics Inc. (DNLI)vs › | $3.06B | -14191.20% | 0.00% | -86.13% | -153.41% |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.88B | 0.00% | 0.00% | 0.00% | 0.00% |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.12B | 0.00% | -172.68% | -306.20% | -1288.24% |
| Tarsus Pharmaceuticals, Inc. (TARS)vs › | $3.19B | -7.67% | -38.94% | -274.32% | -186.92% |
| TransMedics Group, Inc. (TMDX)vs › | $2.77B | 22.69% | 19.73% | -2.42% | -44.65% |
| AtriCure, Inc. (ATRC)vs › | $2.73B | 1.85% | -5.88% | -8.36% | -6.41% |
| MBX Biosciences, Inc. Common Stock (MBX)vs › | $2.71B | 0.00% | 0.00% | 0.00% | 0.00% |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.70B | -33.44% | -12.59% | -3.87% | -6.56% |
Operating Margin
-3.3%
Net Profit Margin
6.2%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 11.56% |
| 2026-03-31 | -10.72% |
| 2025-12-31 | 13.43% |
| 2025-09-30 | 7.47% |
| 2025-06-30 | -19.49% |
| 2025-03-31 | -38.06% |
| 2024-12-31 | -15.12% |
| 2024-09-30 | -92.81% |
| 2024-06-30 | -169.59% |
| 2024-03-31 | -71.38% |
| 2023-12-31 | -490.05% |
| 2023-09-30 | -117.47% |
| 2023-06-30 | -1367.84% |
| 2023-03-31 | -2867.21% |
| 2022-12-31 | -2432.25% |
| 2022-09-30 | -14856.41% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
